52923-25-8

Basic information

• Product Name: (S)-2-(4-fluorophenyl)-2-hydroxyacetic acid
• Synonyms: (S)-2-(4-fluorophenyl)-2-hydroxyacetic acid
• CAS NO: 52923-25-8
• Molecular Weight: 170.14
• Mol File: 52923-25-8.mol
• Article Data: 22

Chemical Properties

• CAS DataBase Reference: (S)-2-(4-fluorophenyl)-2-hydroxyacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(4-fluorophenyl)-2-hydroxyacetic acid(52923-25-8)
• EPA Substance Registry System: (S)-2-(4-fluorophenyl)-2-hydroxyacetic acid(52923-25-8)

Safety Data

• Hazardous Substances Data: 52923-25-8(Hazardous Substances Data)

Usage

Description

(S)-2-(4-fluorophenyl)-2-hydroxyacetic acid, commonly known as flurbiprofen, is a nonsteroidal anti-inflammatory drug (NSAID) derived from propionic acid. It possesses anti-inflammatory and analgesic properties, making it a valuable pharmaceutical compound for the treatment of various conditions characterized by pain and inflammation.

Uses

Used in Pharmaceutical Industry:
Flurbiprofen is used as an analgesic and anti-inflammatory agent for the treatment of [application reason] conditions such as arthritis, menstrual cramps, and dental pain. It achieves this by inhibiting the production of prostaglandins, which are chemicals in the body that cause pain and inflammation.
Used in Oral and Topical Medications:
Flurbiprofen is available in both oral and topical forms, providing patients with different options for administration and treatment. The oral form is typically used for systemic conditions, while the topical form is applied directly to the affected area for localized relief.
However, it is important to note that flurbiprofen, like other NSAIDs, can have side effects including stomach ulcers, gastrointestinal bleeding, and allergic reactions. Therefore, it should be used with caution, especially in patients with a history of these conditions.

Upstream product

• 70122-98-4 [2,2,2-Trichloro-1-(4-fluoro-phenyl)-ethyl]-carbamic acid methyl ester 
• 75-77-4 chloro-trimethyl-silane 
• 151-50-8 potassium cyanide 
• 459-57-4 4-fluorobenzaldehyde 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 77429-21-1 1-methoxycarbonylamino-1-(4-fluorophenyl)-2,2-dichloroethane 
• 134219-54-8 4-Chloro-N-[2,2,2-trichloro-1-(4-fluoro-phenyl)-ethyl]-benzamide 
• 82128-66-3 2-(4-fluorophenyl)-2-(trimethylsilyloxy)acetonitrile 
• 133721-87-6 2-(4-fluorophenyl)-2-hydroxyacetonitrile 
• 462-06-6 fluorobenzene 
• 124-38-9 carbon dioxide 
• 768-33-2 phenyldimethylsilyl chloride 
• 1504663-20-0 [dimethylphenylsilyl(4-fluorophenyl)methoxy]trimethylsilane 
• 1424934-11-1 C₁₅H₁₇FOSi 

Downstream Products

• 456-22-4 4-Fluorobenzoic acid 
• 459-57-4 4-fluorobenzaldehyde 
• 127709-19-7 methyl 4-fluoro-α-hydroxyphenylacetate 
• 2251-76-5 2-(4-fluorophenyl)-2-oxoacetic acid 
• 32222-46-1 (4-fluoro-phenyl)-hydroxy-acetic acid methyl ester 
• 63096-35-5 (4-fluoro-phenyl)-hydroxy-acetic acid methyl ester 
• 959025-07-1 (R)-2-(4-fluorophenyl)-2-hydroxyacetamide 
• 959025-07-1 2-(4-fluorophenyl)-2-hydroxyacetamide 

Relevant articles and documents

Resolution of halogenated mandelic acids through enantiospecific co-crystallization with levetiracetam

The resolution of halogenated mandelic acids using levetiracetam (LEV) as a resolving agent via forming enantiospecific co-crystal was presented. Five halogenated mandelic acids, 2-chloromandelic acid (2-ClMA), 3-chloromandelic acid (3-ClMA), 4-chloromandelic acid (4-ClMA), 4-bromomandelic acid (4-BrMA), and 4-fluoromandelic acid (4-FMA), were selected as racemic compounds. The effects of the equilibrium time, molar ratio of the resolving agent to racemate, amount of solvent, and crystallization temperature on resolution performance were investigated. Under the optimal conditions, the resolution efficiency reached up to 94% and the enantiomeric excess (%e.e.) of (R)-3-chloromandelic acid was 63%e.e. All five halogenated mandelic acids of interest in this study can be successfully separated by LEV via forming enantiospecific co-crystal, but the resolution performance is significantly different. The results showed that LEV selectively co-crystallized with S enantiomers of 2-ClMA, 3-ClMA, 4-ClMA, and 4-BrMA, while it co-crystallized with R enantiomers of 4-FMA. This indicates that the position and type of substituents of racemic compounds not only affect the co-crystal configuration, but also greatly affect the efficiency of co-crystal resolution.

The Synthesis of Chiral α-Aryl α-Hydroxy Carboxylic Acids via RuPHOX-Ru Catalyzed Asymmetric Hydrogenation

A ruthenocenyl phosphino-oxazoline-ruthenium complex (RuPHOX?Ru) catalyzed asymmetric hydrogenation of α-aryl keto acids has been successfully developed, affording the corresponding chiral α-aryl α-hydroxy carboxylic acids in high yields and with up to 97% ee. The reaction could be performed on a gram scale with a relatively low catalyst loading (up to 5000 S/C) and the resulting products can be transformed to several chiral building blocks, biologically active compounds and chiral drugs. (Figure presented.).

Asymmetric hydrogenation reaction of alpha-ketoacids compound

The invention relates to the technical field of organic chemistry, especially to an asymmetric hydrogenation reaction of an alpha-ketoacids compound. The asymmetric hydrogenation reaction comprises a scheme shown in the description. In the scheme, R1 is phenyl, substituted phenyl, naphthyl, substituted naphthyl, C1-C6 alkyl, or aralkyl; a substituent group is C1-C6 alkyl, C1-C6 alkoxy, or halogen; and the number of the substituent group is 1-3. In the scheme, M is a chiral spiro-pyridylamino phosphine ligand iridium complex having a structure shown in the description. In the structure, R is hydrogen, 3-methyl, 4-tBu, or 6-methyl.